Evgen Pharma

United Kingdom
Wilmslow, England, United Kingdom, SK9 4LY

Company profile

Evgen Pharma company profile

Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products.

Business identity

Contact email
[email protected]
Phone number
+44 151 705 3532
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2007-01-01, Year

Headquarters

Postal code
SK9 4LY
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
5
Total equity funding
$16.4M
Last funding
Post IPO Equity / $13.7M / 2021-02-03
Last equity funding
Post IPO Equity / $13.7M
Investors
7
Lead investors
1
Founders
1
Articles
23
Exited on
2015-10-21

Founders and investors

Founders

Stephen Franklin

Lead investors

The North West Fund

Investors

Acceleris CapitalEnterprise VenturesImprimatur CapitalSeneca PartnersThe North West Fund